,i #aaeth ,,congress #ast ,session ,h4 ,r4 #abbc ,,in ,,the ,,house ,,of ,,representatives ,february #bg1 #bjag,mr4 ,bilirakis 7for himself1 ,mr4 ,butterfield1 and ,mr4 ,mc,caul7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,orphan ,products ,extension ,now ,accelerating ,cures and ,treatments ,act of #bjag or the ,,open ,act4 #b4 ,extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #eje;,f of such ,act 7#ba ,u4,s4,c4 #cee;g7 the following3 #eje;,g4 ,extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition 7a7 ,designation 7#a7 ,in general ,the ,secretary shall designate a drug as a drug approved for a new indication to prevent1 diagnose1 or treat a rare disease or condition for purposes of granting the extensions under subsection 7b7 if-- 7,a7 prior to approval of an application or supplemental application for the new indication1 the drug was approved or licensed under section #eje7;c7 of this ,act or section #cea7;a7 of the ,public ,health ,service ,act but was not so approved or licensed for the new indication2 7,b7 7i7 the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent1 diagnose1 or treat the rare disease or condition2 and 7ii7 the ,secretary approves the application or supplemental application2 and 7,c7 the application or supplemental application for the new indication contains the consent of the applicant to public notice under paragraph 7#d7 with respect to the designation of the drug4 7#b7 ,revocation of designation 7,a7 ,in general ,except as provided in subparagraph 7,b71 a designation under paragraph 7#a7 shall not be revoked for any reason4 7,b7 ,exception ,the ,secretary may revoke a designation of a drug under paragraph 7#a7 if the ,secretary finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact4 7#c7 ,notice to public ,the ,secretary shall provide public notice of the designation of a drug under paragraph 7#a74 7b7 ,extension 7#a7 ,in general ,if the ,secretary designates a drug as a drug approved for a new indication for a rare disease or condition1 as described in subsection 7a77#a7-- 7,a7 7i7 the #d-1 #e-1 and #g-year periods described in subsections 7c77#c77;,e77ii7 and 7j77#e77;,f77ii7 of section #eje1 the #c-year periods described in clauses 7iii7 and 7iv7 of subsection 7c77#c77;,e7 and clauses 7iii7 and 7iv7 of subsection 7j77#e77;,f7 of section #eje1 and the #g-year period described in section #ebg1 as applicable1 shall be extended by #f months2 or 7ii7 the #d- and #ab-year periods described in subparagraphs 7,a7 and 7,b7 of section #cea7k77#g7 of the ,public ,health ,service ,act and the #g-year period described in section #ebg1 as applicable1 shall be extended by #f months2 and 7,b7 7i7 if the drug is the subject of a listed patent for which a certification has been submitted under subsection 7b77#b77;,a77ii7 or 7j77#b77;,a77vii77,,ii7 of section #eje or a listed patent for which a certification has been submitted under subsection 7b77#b77;,a77iii7 or 7j77#b77;,a77vii77,,iii7 of section #eje1 the period during which an application may not be approved under section #eje7;c77#c7 or section #eje7;j77#e77;,b7 shall be extended by a period of #f months after the date the patent expires 7including any patent extensions72 or 7ii7 if the drug is the subject of a listed patent for which a certification has been submitted under subsection 7b77#b77;,a77iv7 or 7j77#b77;,a77vii77,,iv7 of section #eje1 and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed1 the period during which an application may not be approved under section #eje7;c77#c7 or section #eje7;j77#e77;,b7 shall be extended by a period of #f months after the date the patent expires 7including any patent extensions74 7#b7 ,relation to pediatric and qualified infectious disease product exclusivity ,any extension under paragraph 7#a7 of a period shall be in addition to any extension of the periods under sections #eje;,a and #eje;,e of this ,act and section #cea7m7 of the ,public ,health ,service ,act1 as applicable1 with respect to the drug4 7c7 ,limitations ,any extension described in subsection 7b77#a7 shall not apply if the drug designated under subsection 7a77#a7 has previously received an extension by operation of subsection 7b77#a74 7d7 ,definition ,in this section1 the term rare disease or condition has the meaning given to such term in section #ebf7;a77#b74 4 7b7 ,application ,section #eje;,g of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 applies only with respect to a drug for which an application or supplemental application described in subsection 7a77#a77;,b77i7 of such section #eje;,g is first approved under section #eje7;c7 of such ,act 7#ba ,u4,s4,c4 #cee7;c77 or section #cea7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;a77 on or after the date of the enactment of this ,act4 7c7 ,conforming amendments 7#a7 ,relation to pediatric exclusivity for drugs ,section #eje;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;a7 is amended-- 7,a7 in subsection 7b71 by adding at the end the following3 7#c7 ,relation to exclusivity for a drug approved for a new indication for a rare disease or condition ,notwithstanding the references in paragraph 7#a7 to the lengths of the exclusivity periods after application of pediatric exclusivity1 the #f-month extensions described in paragraph 7#a7 shall be in addition to any extensions under section #eje;,g4 2 and 7,b7 in subsection 7c71 by adding at the end the following3 7#c7 ,relation to exclusivity for a drug approved for a new indication for a rare disease or condition ,notwithstanding the references in paragraph 7#a7 to the lengths of the exclusivity periods after application of pediatric exclusivity1 the #f-month extensions described in paragraph 7#a7 shall be in addition to any extensions under section #eje;,g4 4 7#b7 ,relation to exclusivity for new qualified infectious disease products that are drugs ,subsection 7b7 of section #eje;,e of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;f7 is amended-- 7,a7 by amending the subsection heading to read as follows3 ,relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition4--2 and 7,b7 by striking any extension of the period under section #eje;,a and inserting any extension of the periods under sections #eje;,a and #eje;,g1 as applicable14 7#c7 ,relation to pediatric exclusivity for biological products ,section #cea7m7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7m77 is amended by adding at the end the following3 7#e7 ,relation to exclusivity for a biological product approved for a new indication for a rare disease or condition ,notwithstanding the references in paragraphs 7#b77;,a71 7#b77;,b71 7#c77;,a71 and 7#c77;,b7 to the lengths of the exclusivity periods after application of pediatric exclusivity1 the #f-month extensions described in such paragraphs shall be in addition to any extensions under section #eje;,g4 4